Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This study identified TGF-β2 as a crucial signal in hair follicle stem cell regeneration, highlighting its role in counteracting BMP signaling to promote tissue regeneration.

This study found that both 2.5 mg/mL and 5 mg/mL concentrations of intralesional triamcinolone acetonide are effective for treating patchy alopecia areata, but the higher concentration promoted greater hair regrowth and density with more side effects.

This review discusses the Activin/Nodal signalling pathway's role in stem cell function and its implications in cancer therapy, reporting no new experimental results but highlighting future research questions.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.

This abstract contains only author affiliations and mentions the Asian Association of Hair Restoration Surgeons, without presenting any new research findings.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that the catalytically inactive serine protease CAP1/Prss8 can still induce skin disorders in mice and is subject to inhibition by nexin-1, independent of its catalytic activity.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study presents the crystal structure of human SRD5A2 with finasteride and reveals insights into its enzyme catalysis and inhibition mechanisms, which may inform drug development.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study observed that the small molecules KY19382 and KY19334 inhibited cancerous traits in human cutaneous squamous cell carcinoma cells by suppressing the Wnt/β-catenin pathway, indicating their potential as treatments for cancers involving CDK1 overexpression and diseases related to CXXC5 accumulation.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

This study observed that PAI-2 is consistently expressed in differentiating cells of murine hair and nail, suggesting it may function as a marker of differentiation and possibly protect against premature cell death.

This study found that the loss of transcription factor Ovol2 in epidermal and hair follicle stem cells leads to migration defects, which are partially improved by deleting the EMT-inducing Zeb1.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study found that increased mRNA expression of the Ectodysplasin-A2-Receptor, observed across multiple species and tissues, may exacerbate inflammation during aging, suggesting potential benefits of blocking EDA2R/EDA-A2 signaling.

This study concluded that transgenic somatic cell nuclear transfer technology can produce cashmere goat blastocysts carrying the K2.9 gene using specific fibroblast cells and activation methods.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this study, 12-Chloracetyl-PPD showed anti-cancer activity by inhibiting cancer cell viability and inducing apoptosis through reactive oxygen species production without harming normal cells.

This study reported a rare case where a pheochromocytoma produced ACTH, leading to cyclic Cushing syndrome, and underscores the importance of considering this possibility in cases of ACTH-dependent hypercortisolism with an adrenal mass.